Browsing by Author "Dişel, Umut"
Now showing items 1-5 of 5
-
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study
Ölmez, Ömer Fatih; Bilici, Ahmet; Er, Özlem; Bişgin, Atıl; Sevinç, Alper; Akman, Tülay; Uslu, Rüçhan; Molinas Mandel, Nil; Yalçın, Şuayib; Teomete, Mehmet; Görümlü, Gürbüz; Demir, Atakan; Namal, Esat; Alıcı, Süleyman; Selçukbiricik, Fatih; Bavbek, Sevil; Paksoy, Fatma; Başaran, Gül; Özer, Leyla; Şener, Nur; Harputluoğlu, Hakan; Kaya, Ali Osman; Yazar, Aziz; Afşar, Çiğdem Usul; Göker, Erdem; Şen, Fatma; Gököz Doğu, Gamze; Şeker, Mesut; Özkan, Metin; Türken, Orhan; Özveren, Ahmet; Orhan, Bülent; Yumuk, Fulden; Üskent, Necdet; Saip, Pınar; Şanlı, Ulus Ali; Dişel, Umut; Berk, Veli; Alakavuklar, Mehmet (2024)Objective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced ... -
Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.
Bişgin, Atıl; Boğa, İbrahim; Eskut, Kaan İhsan; Rencüzoğulları, Çağla; Sönmezler, Özge; Köse, Fatih; Beşen, Ali Ayberk; Ölmez, Ömer Fatih; Dişel, Umut; Koçer, Nazım Emrah; Bolat, Filiz; Jinga, Dan-Corneliu; Lazar, Ioana; Pathak, Surajit (Lippincott Williams & Wilkins, 2023)... -
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
Gürbüz, Mustafa; Kılıçkap, Saadettin; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Fulden Yumuk, Perran; Gürsoy, Pınar; Uysal, Mükremin; Şenol Coşkun, Hasan; Tatlı, Ali Murat; Selçukbiricik, Fatih; Dişel, Umut; Köksoy, Elif Berna; Güven, Deniz Can; Uğraklı, Muzaffer; Akkuş, Erman; Yücel, Şebnem; Erol, Cihan; Karakaya, Serdar; Şakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazık, Ahmet (NLM (Medline), 2022)Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib ... -
The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors
Dişel, Umut; Köse, Fatih; Bilici, Ahmet; Özgüroğlu, Mustafa; Sağlam, Sezer; Şeker, Mesut; Aksoy, Sercan; Tek, İbrahim; Mandel, Nil Molinas; Demir, Gökhan; Arslan, Çağatay; Demiray, Mutlu; Öztürk, Mehmet Akif; Salepçi, Taflan; Eralp, Yeşim; Selçukbiricik, Fatih; Temizaş, Gökçe; Fidan, Ebru Gül (Turkiye Klinikleri, 2022)Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact ... -
Real-world efficacy and safety of first-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A nationwide observational Turkish Oncology Group (TOG) study
Kutlu, Yasin; Dae, Shute Ailia; Yılmaz, Feride; Erdem, Dilek; Şendur, Mehmet Ali Nahit; Akbaş, Sinem; Şenocak Taşçı, Elif; Baş, Onur; Dane, Faysal; Sakin, Abdullah; Kaya, Ali Osman; Aykan, Musa Barış; Ergün, Yakup; Biter, Sedat; Dişel, Umut; Korkmaz, Mustafa; Selçukbiricik, Fatih; Köse, Fatih; Ölmez, Ömer Fatih; Bilici, Ahmet; Demir, Gökhan; Yalçın, Şuayib (2024)Based on the CheckMate 649 trial, nivolumab plus chemotherapy is the recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. ...
